We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Catalyst Pharmaceuticals Inc
13 own
32 watching
Current Price
$0
$0.03
(0.25%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,256.43M
52-Week High
22.11
52-Week Low
6.15
Average Volume
0.09M
Dividend Yield
--
P/E Ratio
9.1246
Market Capitalization1,256.43M52-Week High22.1152-Week Low6.15Average Volume0.09MDividend Yield--P/E Ratio9.1246What does the Catalyst Pharmaceuticals Inc do?
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Read More
How much money does Catalyst Pharmaceuticals Inc make?
News & Events about Catalyst Pharmaceuticals Inc.
Globe Newswire
1month ago
CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases today announced ...
Benzinga
2 months ago
read more...
Globe Newswire
3 months ago
CORAL GABLES, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases...
Globe Newswire
3 months ago
The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ETCORAL GABLES, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.(Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and ...
Globe Newswire
3 months ago
Spotlight On Raising Awareness for Rare Diseases on February 28, 2023 Celebrating the Tireless Contributions of Patients and Advocates who Work with the Biotech Industry to Bring New Treatments to the Community CORAL GABLES, Fla., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc., (...
Frequently Asked Questions
Frequently Asked Questions
What is Catalyst Pharmaceuticals Inc share price today?
Can Indians buy Catalyst Pharmaceuticals Inc shares?
How can I buy Catalyst Pharmaceuticals Inc shares from India?
Can Fractional shares of Catalyst Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Catalyst Pharmaceuticals Inc stocks?
What is today’s traded volume of Catalyst Pharmaceuticals Inc?
What is today’s market capitalisation of Catalyst Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Catalyst Pharmaceuticals Inc?
What percentage is Catalyst Pharmaceuticals Inc down from its 52-Week High?
What percentage is Catalyst Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$0
$0.03
(0.25%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.